Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Anthony Moorman

Newcastle AuthorsTitleYearFull text
Dr Jack Bakewell
Professor Anthony Moorman
Sarra Ryan
DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum2025
Professor Anthony Moorman
IGH rearrangements in Down syndrome acute lymphoblastic leukemia2025
Professor Anthony Moorman
PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome2025
Sarra Ryan
Emerita Professor Christine Harrison
Professor Anthony Moorman
A dedicated caller for DUX4 rearrangements from whole-genome sequencing data2025
Professor Anthony Moorman
ALLTogether recommendations for biobanking samples from patients with acute lymphoblastic leukaemia: a modified Delphi study: Clinical Studies2025
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.		Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia (Cancer Cell International, (2023), 23, 1, (202), 10.1186/s12935-023-03057-8)2025
Dr Sarra Ryan
Dr Lisa Russell
Professor Anthony Moorman
Excised DNA circles from V(D)J recombination promote relapsed leukaemia2025
Professor Anthony Moorman
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?2024
Dr Amir Enshaei
Melvin Joy
Ellie Butler
Professor Anthony Moorman
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study2024
Dr Hayden Bell
Dr Helen Blair
Samantha Jepson Gosling
Dr Martin Galler
Dan Astley
et al.		Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2024
Professor Anthony Moorman
Melvin Joy
Dr Amir Enshaei
Emerita Professor Christine Harrison
Dr Claire Schwab
et al.		De-intensifying post-induction therapy for patients with acute lymphoblastic leukaemia, good risk genetics and intermediate MRD at the end of induction2024
Ozcan Gulbey
Dr Amir Enshaei
Melvin Joy
Dr Sujith Samarasinghe
Professor Anthony Moorman
Early response refines end of induction measurable residual disease stratification in T-cell acute lymphoblastic leukaemia2024
Professor Anthony Moorman
Dr Amir Enshaei
Daniel Murdy
Melvin Joy
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction2024
Professor Anthony Moorman
Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL2024
Emilio Barretta
Dr Tom Creasey
Professor Anthony Moorman
Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia2024
123456789101112131415161718